You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 4, April 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Association of Increased Cortical Soluble Aβ42 Levels With Diffuse Plaques After Severe Brain Injury in Humans

Steven T. DeKosky, MD; Eric E. Abrahamson, PhD; John R. Ciallella, PhD; William R. Paljug, MS; Stephen R. Wisniewski, PhD; Robert S. B. Clark, MD; Milos D. Ikonomovic, MD

Arch Neurol. 2007;64(4):541-544.

Background  Traumatic brain injury (TBI) is an environmental risk factor for developing Alzheimer disease. This may be due, in part, to changes associated with β-amyloid (Aβ) plaque formation, which can occur within hours after injury, regardless of the patient's age. In addition to being precursors of toxic fibrils that deposit into plaques, soluble (nonfibrillar) Aβ peptides are posited to disrupt synaptic function and are associated with cognitive decline in Alzheimer disease. Changes in soluble Aβ levels and their relationship to Aβ plaque formation following TBI are unknown.

Objective  To quantify brain tissue levels of soluble Aβ peptides and their precursor protein in relation to Aβ plaque formation after TBI in humans.

Design  Surgically resected temporal cortex tissue from patients with severe TBI was processed for biochemical assays of soluble Aβ peptides with COOH-termini ending in amino acid 40 (Aβ40) or 42 (Aβ42) and Aβ precursor protein to compare patients with cortical Aβ plaques and those without.

Patients  Nineteen subjects admitted to the University of Pittsburgh Medical Center for treatment of severe closed head injury.

Results  Patients with severe TBI and cortical plaques had higher levels of soluble Aβ1-42 but not Aβ1-40; half of them were apolipoprotein E (APOE) {varepsilon}4 allele carriers. The lowest Aβ levels were in 1 patient without plaques who was the only subject with an APOE {varepsilon}2 allele. β-Amyloid precursor protein levels were comparable in the 2 TBI groups.

Conclusions  Selective increases in soluble Aβ1-42 after TBI may predispose individuals with a brain injury to Alzheimer disease pathology. This may be influenced by the APOE genotype, and it may confer increased risk for developing Alzheimer disease later in life.


Author Affiliations: Departments of Neurology (Drs DeKosky, Abrahamson, Ciallella, and Ikonomovic, and Mr Paljug), Psychiatry (Drs DeKosky and Ikonomovic), and Critical Care Medicine (Dr Clark), and Epidemiology Data Center, Graduate School of Public Health (Dr Wisniewski), University of Pittsburgh School of Medicine, Pittsburgh, Pa.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Potential for Estrogens in Preventing Alzheimer's Disease.
Simpkins et al.
Therapeutic Advances in Neurological Disorders 2009;2:31-49.
ABSTRACT  

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic et al.
Brain 2008;131:1630-1645.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.